ETRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Electra Therapeutics, Inc.
$8.61−0.14 (-1.60%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0M
Shares held, 13F filers
Institutional holders
0
0 new, 1 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
4 buys · 0 sales
Net bought $40.00M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Orbimed Advisors LLC | 6,885,170 | 11.00% | 13D (active) | Sep 21, 2026 |
| Redmile Group, LLC | 5,462,881 | 8.70% | 13G (passive) | Sep 21, 2026 |
| LSP 7 Cooperatief U.A. | 3,795,281 | 6.00% | 13G (passive) | Sep 21, 2026 |
Top institutional holders
13F holdings as of Mar 31, 2026
| Holder | Shares | % of ETRA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Kentucky Retirement Systems | 23,712 | – | $466 | New | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 0 | 0M | 0 / 0 | 0 / 1 | 0M | 0M |
| Q1 2026 | 1 | 0M | 1 / 0 | 0 / 0 | 0M | 0M |
| Q1 2025 | 0 | 0M | 0 / 0 | 0 / 1 | 0M | 0M |
| Q4 2024 | 1 | 0M | 1 / 0 | 0 / 0 | 0M | 0M |
| Q4 2021 | 0 | 0M | 0 / 0 | 0 / 1 | 0M | 0M |
| Q3 2021 | 1 | 0M | 1 / 0 | 0 / 0 | 0M | 0M |
| Q1 2021 | 0 | 0M | 0 / 0 | 0 / 2 | 0M | 0M |
| Q4 2020 | 2 | 0M | 1 / 0 | 0 / 407 | 0M | 204M |
| Q3 2020 | 410 | 204M | 43 / 122 | 173 / 40 | 16M | 25M |
| Q2 2020 | 407 | 213M | 57 / 110 | 189 / 61 | 30M | 33M |
| Q1 2020 | 412 | 217M | 64 / 119 | 184 / 119 | 63M | 59M |
| Q4 2019 | 473 | 213M | 83 / 142 | 194 / 69 | 38M | 34M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Quehuong (Kathy) Dong | President & CEO, Director | 455,484 | Sep 21, 2026 |
| Gary S. Koe | Chief Technical Officer | 63,656 | Sep 21, 2026 |
| Graham Parry | Chief Scientific Officer | 85,504 | Sep 21, 2026 |
| David J. Tucker | Principal Accounting Officer | – | Sep 18, 2026 |
| Christopher William Clark | Chief Financial Officer | – | Sep 18, 2026 |
| Kim-Hien Dao | Chief Medical Officer | – | Sep 18, 2026 |
| Carl L. Gordon | Director, 10% owner | 758,279 | Sep 23, 2026 |
| Genesis GP LLC OrbiMed | Director, 10% owner | – | Sep 23, 2026 |
| Capital GP VII LLC OrbiMed | Director, 10% owner | 5,126,891 | Sep 23, 2026 |
| Advisors Llc Orbimed | Director, 10% owner | – | Sep 23, 2026 |
| Nancy Stagliano | Director | 255,635 | Sep 21, 2026 |
| Matthew K. Fust | Director | – | Sep 18, 2026 |
| Westlake BioPartners Fund I, L.P. | 10% owner | – | Sep 21, 2026 |
| Westlake BioPartners GP I, LLC | 10% owner | – | Sep 21, 2026 |
| Westlake BioPartners GP II, LLC | 10% owner | – | Sep 21, 2026 |
| Westlake BioPartners Fund II, L.P. | 10% owner | 2,820,403 | Sep 21, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Capital GP VII LLC OrbiMed Director, 10% owner | Sep 21, 2026 | Buy | +333,333 | $15.00 | $5.00M | 5,126,891 |
| Capital GP VII LLC OrbiMed Director, 10% owner | Sep 21, 2026 | Conversion | +1,087,934 | – | – | 3,090,244 |
| Capital GP VII LLC OrbiMed Director, 10% owner | Sep 21, 2026 | Buy | +1,000,000 | $15.00 | $15.00M | 1,758,279 |
| Capital GP VII LLC OrbiMed Director, 10% owner | Sep 21, 2026 | Conversion | +758,279 | – | – | 758,279 |
| Capital GP VII LLC OrbiMed Director, 10% owner | Sep 21, 2026 | Conversion | +1,703,314 | – | – | 4,793,558 |
| Capital GP VII LLC OrbiMed Director, 10% owner | Sep 21, 2026 | Conversion | +2,002,310 | – | – | 2,002,310 |
| Carl L. Gordon Director, 10% owner | Sep 21, 2026 | Conversion | +758,279 | – | – | 758,279 |
| Carl L. Gordon Director, 10% owner | Sep 21, 2026 | Conversion | +2,002,310 | – | – | 2,002,310 |
| Carl L. Gordon Director, 10% owner | Sep 21, 2026 | Conversion | +1,087,934 | – | – | 3,090,244 |
| Carl L. Gordon Director, 10% owner | Sep 21, 2026 | Buy | +1,000,000 | $15.00 | $15.00M | 1,758,279 |
| Carl L. Gordon Director, 10% owner | Sep 21, 2026 | Conversion | +1,703,314 | – | – | 4,793,558 |
| Carl L. Gordon Director, 10% owner | Sep 21, 2026 | Buy | +333,333 | $15.00 | $5.00M | 5,126,891 |
| Gary S. Koe Chief Technical Officer | Sep 21, 2026 | Conversion | +63,656 | – | – | 63,656 |
| Graham Parry Chief Scientific Officer | Sep 21, 2026 | Conversion | +85,504 | – | – | 85,504 |
| Quehuong (Kathy) Dong President & CEO, Director | Sep 21, 2026 | Conversion | +455,484 | – | – | 455,484 |
| Nancy Stagliano Director | Sep 21, 2026 | Conversion | +255,635 | – | – | 255,635 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.